direclidine Updated Nov 3
The next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.
- Direclidine is a selective M4 orthosteric agonist, a differentiated mechanism from Cobenfy (which combines M1/M4 agonism with a peripheral blocker). If direclidine shows a cleaner side-effect profile or once-daily dosing advantage, it could carve out a meaningful share of the large schizophrenia market.
- Phase 2 data showed a statistically significant 7.5-point PANSS improvement at the 20 mg dose (p=0.011, effect size 0.61) with generally good tolerability, providing a solid foundation for the Phase 3 registrational program.
- Neurocrine is a well-capitalized company with INGREZZA generating over $1.1B in quarterly revenue, giving it the resources to fully commercialize direclidine without partnership dependence.
- Direclidine faces a first-mover disadvantage: Bristol Myers Squibb's Cobenfy (KarXT, xanomeline/trospium) was FDA-approved for schizophrenia in September 2024 and is already on the market, establishing the muscarinic agonist class and potentially capturing prescriber mindshare before direclidine can reach Phase 3 readout.
- Phase 3 trials in schizophrenia are notoriously high-risk; the Phase 2 study showed statistical significance only at the 20 mg dose (not at higher doses), raising questions about the therapeutic window and dose-response curve.
- Topline data from the ongoing Phase 3 program is not expected until 2027 at the earliest, and some trials may read out as late as 2028, meaning no near-term binary catalyst and a long wait for investors.